

## Results of Annual General Meeting

**Melbourne, Australia, 24 November 2021:** Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, announces the following:

In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders of the Company, at its Annual General Meeting of shareholders held on 24 November, 2021.

All resolutions put to the meeting were passed on a poll, called by the Chairman pursuant to the Notice of Meeting.

A summary of the Poll voting results is set out on the following page.

Authorised by:  
Mike Tonroe  
Company Secretary  
On behalf of the Board of Directors  
Genetic Technologies Limited  
+61 3 8412 7000

### Investor Relations (AUS)

Stephanie Ottens  
Market Eye  
M: +61 434 405 400  
E: [stephanie.ottens@marketeye.com.au](mailto:stephanie.ottens@marketeye.com.au)

### Investor Relations and Media (US)

Dave Gentry  
1 800 RED CHIP (733 2447)  
Cell: 407 491 4498  
E: [dave@redchip.com](mailto:dave@redchip.com)

### About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit [www.genetype.com](http://www.genetype.com)

**Genetic Technologies Limited**  
**2021 Annual General Meeting**  
**Wednesday, 24 November 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1 Adoption of the Remuneration Report	Ordinary	518,957,497 74.20%	98,198,665 14.04%	82,282,672 11.76%	242,585,128	603,914,770 86.01%	98,198,665 13.99%	242,585,128	Carried	
2 Re-Election of Dr Jerzy (George) Muchnicki	Ordinary	945,175,413 69.66%	302,407,169 22.29%	109,139,815 8.05%	22,273,427	1,056,989,829 77.75%	302,407,169 22.25%	22,273,427	Carried	
3 Approval of proposed issue of Warrants	Ordinary	1,035,079,989 75.87%	223,794,596 16.40%	105,450,704 7.73%	14,671,135	1,143,205,294 83.63%	223,794,596 16.37%	14,671,135	Carried	
4 Prior issue of Shares under ASX Listing Rule 7.1	Ordinary	1,033,906,035 76.30%	215,762,182 15.92%	105,362,672 7.78%	23,964,935	1,141,943,308 84.11%	215,762,182 15.89%	23,964,935	Carried	
5 Prior issue of Shares under ASX Listing Rule 7.1A	Ordinary	1,025,496,635 75.68%	223,876,982 16.52%	105,647,672 7.80%	23,974,535	1,133,818,908 83.51%	223,876,982 16.49%	23,974,535	Carried	
6 Adoption of Employee Share and Option Plan	Ordinary	720,201,862 76.43%	116,797,050 12.39%	105,389,815 11.18%	23,805,235	805,766,278 87.34%	116,797,050 12.66%	23,805,235	Carried	
7 Approval of Increased Placement Capacity	Special	960,067,508 71.35%	280,100,666 20.82%	105,389,815 7.83%	33,438,435	1,068,131,924 79.22%	280,100,666 20.78%	33,438,435	Carried	

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.